



## **Prescription drug manufacturers are refusing to honor pricing programs**

Major prescription drug manufacturers such as AstraZeneca and Eli Lilly and other major prescription drug manufacturers have recently refused to provide discount pricing to hospitals and FQHCs who qualify for the 340B prescription drug program.

Below is a proposed amendment that would ensure prescription drug manufacturers honor the 340B program and any other discount or government-negotiated prescription drug program, creating great predictability for hospitals and FQHCs.

*This proposed amendment is based on [Arkansas law](#).*

### **Chapter 91: Prescription Drug Cost Containment**

#### **Subchapter 5 Preferential Drug Pricing**

##### **18 VSA §4660 Prohibition on interference in preferential pricing programs**

(a) A hospital or clinic in this state that is entitled to preferential pricing on outpatient prescription drugs under federal or state law or by contract may purchase such drugs at preferential prices and arrange for their shipment to a duly licensed pharmacy under contract with the hospital or clinic for purposes of dispensing such drugs on behalf of the hospital or clinic.

(b) No manufacturer or supplier of such preferentially priced outpatient drugs may deny shipment of such drugs to the hospital's or clinic's contract pharmacy, or place conditions or restrictions on their sale.